4yr
Conclusions and Relevance: The findings of this targeted evidence update are generally consistent with the findings of the previous systematic review supporting the 2016 USPSTF recommendation. Evidence of pharmacologic treatment was still largely limited to persons with moderate airflow obstruction, and there was no consistent benefit observed for a range of nonpharmacologic interventions in mild to moderate COPD or in minimally symptomatic persons with COPD.
• Source: JAMA
• Conclusion: “The findings of this targeted evidence update are generally consistent with the findings of the previous systematic review supporting the 2016 recommendation. Evidence of pharmacologic treatment was still largely limited to persons with moderate airflow obstruction, and there was no consistent benefit observed for a range of nonpharmacologic interventions in mild to moderate COPD or in minimally symptomatic persons with COPD.”
• In 2008 and 2016, the US Preventive Services Task Force (USPSTF) issued a D recommendation against COPD screening for COPD in asymptomatic adults.
• This targeted systematic review examined the evidence on the effectiveness of screening for COPD and the treatment of COPD to inform the US Preventive Services Task Force (USPSTF) update of the 2016 recommendation statement on COPD screening. No treatment studies were examined.
• The only benefit of screening exhibited was decreased COPD exacerbations with no benefits in dyspnea, mortality, or quality of life.
• One limitation of the current t study is that investigators only included studies of treatment benefits or harms in those with mild to moderate COPD, as well as those who were asymptomatic. The investigators did not include FEV1 measures.